Skip to main content
Erschienen in: Familial Cancer 1/2013

01.03.2013 | Original Article

Multiple small “imaging” branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia?

verfasst von: D. K. Bartsch, K. Dietzel, M. Bargello, E. Matthaei, G. Kloeppel, I. Esposito, J. T. Heverhagen, T. M. Gress, E. P. Slater, P. Langer

Erschienen in: Familial Cancer | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Most screening programs for familial pancreatic cancer are currently based on endoscopic ultrasonography and/or magnetic resonance imaging (MRI). Cystic lesions, especially those suspicious for small intraductal pancreatic mucinous neoplasms (IPMNs) of the branch ducts, can be visualized in up to 40 % of individuals at risk, but their pathological importance in the setting of FPC is yet not well established. Individuals at risk from a prospective screening program for familial pancreatic cancer with small “imaging” IPMNs of the branch-duct type (BD-IPMN) who underwent pancreatic resection were analysed regarding clinico-pathological data and the locations of pancreatic lesions. Five of 125 individuals at risk who underwent screening had multiple small (size 2–10 mm) unicystic lesions and/or multicystic single lesions in the pancreatic body and tail suspicious for BD-IPMNs upon MRI imaging and decided to undergo surgical resection after interdisciplinary counselling, although none fulfilled the consensus criteria for IPMN resection. Histological examination revealed BD-IPMNs with low or moderate dysplasia of the gastric type in combination with multifocal PanIN2 and PanIN3 lesions in 4 individuals. The remaining patient had only tiny ductectasias in the pancreatic tail with multifocal PanIN 2 lesions in the entire gland and one PanIN3 lesion in the pancreatic head. Intriguingly, the location of the most dysplastic histological lesions (PanIN3) did not correspond to the preoperatively detected lesions and were not visible in preoperative imaging. In the setting of FPC, the presence of multiple small “imaging” BD-IPMNs may indicate the presence of high-grade PanIN lesions elsewhere in the pancreas.
Literatur
2.
Zurück zum Zitat Bartsch DK, Sina-Frey M, Ziegler A, Hahn SA, Pryzpadlo E, Kress R, Gerdes B, Rieder H (2001) Update of familial pancreatic cancer in Germany. Pancreatology 1:510–516PubMedCrossRef Bartsch DK, Sina-Frey M, Ziegler A, Hahn SA, Pryzpadlo E, Kress R, Gerdes B, Rieder H (2001) Update of familial pancreatic cancer in Germany. Pancreatology 1:510–516PubMedCrossRef
3.
Zurück zum Zitat Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B, Kress R, Ziegler A, Raeburn JA, Campra D, Grützmann R, Rehder H, Rothmund M, Schmiegel W, Nepoptolemus JP, Bartsch DK (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214–221PubMedCrossRef Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B, Kress R, Ziegler A, Raeburn JA, Campra D, Grützmann R, Rehder H, Rothmund M, Schmiegel W, Nepoptolemus JP, Bartsch DK (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214–221PubMedCrossRef
4.
Zurück zum Zitat Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, Hruban RA, Kern SE (2002) Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 117 %. Cancer Res 62:3789–3793PubMed Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, Hruban RA, Kern SE (2002) Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 117 %. Cancer Res 62:3789–3793PubMed
5.
Zurück zum Zitat Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324:217–220PubMedCrossRef Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324:217–220PubMedCrossRef
6.
Zurück zum Zitat Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N, Neoplotemos JP, Greenhalf W, Bartsch DK (2010) PALB2 mutations in European familial pancreatic cancer families. Clin Genet 78:490–494PubMedCrossRef Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N, Neoplotemos JP, Greenhalf W, Bartsch DK (2010) PALB2 mutations in European familial pancreatic cancer families. Clin Genet 78:490–494PubMedCrossRef
7.
Zurück zum Zitat Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, Gallinger S, Schwartz AG, Syngal S, Cote ML, Axilbund J, Schulick R, Ali SZ, Eshleman JR, Velculescu VE, Goggins M, Vogelstein B, Papadopoulos N, Hruban RH, Kinzler KW, Klein AP (2011) ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2:41–46PubMedCrossRef Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, Gallinger S, Schwartz AG, Syngal S, Cote ML, Axilbund J, Schulick R, Ali SZ, Eshleman JR, Velculescu VE, Goggins M, Vogelstein B, Papadopoulos N, Hruban RH, Kinzler KW, Klein AP (2011) ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2:41–46PubMedCrossRef
8.
Zurück zum Zitat Brand RE, Lerch MM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH, Brentnall TA, Lynch HT, Canto MI (2007) Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56:1460–1469PubMedCrossRef Brand RE, Lerch MM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH, Brentnall TA, Lynch HT, Canto MI (2007) Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56:1460–1469PubMedCrossRef
9.
Zurück zum Zitat Canto MI, Harink F, Hruban RH, Offerhaus J, Poley J-W, Fockens P, Kamel IR, Nio CY, Schulick RD, Basel C, Kluijt I, Goggins MG, Bruno MJ (2012) On behalf of the International CAPS Consortium. International consensus recommendations on the management of patients with increased risk for familial pancreatic cancer (Cancer of the Pancreas Screening Consortium (CAPS) 2011 Summit), to be presented at the Digestive Disease Week (DDW), San Diego, California, USA, May 19–May 22 Canto MI, Harink F, Hruban RH, Offerhaus J, Poley J-W, Fockens P, Kamel IR, Nio CY, Schulick RD, Basel C, Kluijt I, Goggins MG, Bruno MJ (2012) On behalf of the International CAPS Consortium. International consensus recommendations on the management of patients with increased risk for familial pancreatic cancer (Cancer of the Pancreas Screening Consortium (CAPS) 2011 Summit), to be presented at the Digestive Disease Week (DDW), San Diego, California, USA, May 19–May 22
10.
Zurück zum Zitat Bartsch DK, Gress TM, Langer P (2012) Familial pancreatic cancer-current knowledge. Nat Rev Gastroenenterol Hepatol, ahead of print Bartsch DK, Gress TM, Langer P (2012) Familial pancreatic cancer-current knowledge. Nat Rev Gastroenenterol Hepatol, ahead of print
11.
Zurück zum Zitat Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, Topazian M, Takahashi N, Fletcher J, Petersen G, Klein AP, Axilbund J, Griffin C, Syngal S, Saltzman JR, Mortele KJ, Lee J, Tamm E, Vikram R, Bhosale P, Margolis D, Farrell J, Goggins M (2012) American cancer of the pancreas screening (CAPS) consortium. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142(4):796–804PubMedCrossRef Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, Topazian M, Takahashi N, Fletcher J, Petersen G, Klein AP, Axilbund J, Griffin C, Syngal S, Saltzman JR, Mortele KJ, Lee J, Tamm E, Vikram R, Bhosale P, Margolis D, Farrell J, Goggins M (2012) American cancer of the pancreas screening (CAPS) consortium. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142(4):796–804PubMedCrossRef
12.
Zurück zum Zitat Ohashi K, Murakami Y, Takekoshi T (1982) Four cases of mucin-producing cancer of the pancreas on specific findings of the papilla of Vater. Progn Diagn Endosc 20:348–351 Ohashi K, Murakami Y, Takekoshi T (1982) Four cases of mucin-producing cancer of the pancreas on specific findings of the papilla of Vater. Progn Diagn Endosc 20:348–351
13.
Zurück zum Zitat Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, Yamaguchi K, Yamao K, Matsuno S (2006) International consensus guidelines for management of intraductal papillary mucinous neoplas and mucinous cystic neoplasms of the pancreas. Pancreatology 6:17–32PubMedCrossRef Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, Yamaguchi K, Yamao K, Matsuno S (2006) International consensus guidelines for management of intraductal papillary mucinous neoplas and mucinous cystic neoplasms of the pancreas. Pancreatology 6:17–32PubMedCrossRef
14.
Zurück zum Zitat Bussom S, Saif MW (2010) Intraductal papillary mucinous neoplasia (IPMN). JOP 11:131–134PubMed Bussom S, Saif MW (2010) Intraductal papillary mucinous neoplasia (IPMN). JOP 11:131–134PubMed
15.
Zurück zum Zitat Uehara H, Nakaizumi A, Ishikawa O, Iishi H, Tatsumi K, Takakura R, Ishida T, Takano Y, Tanaka S, Takenaka A (2008) Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut 57:1561–1565PubMedCrossRef Uehara H, Nakaizumi A, Ishikawa O, Iishi H, Tatsumi K, Takakura R, Ishida T, Takano Y, Tanaka S, Takenaka A (2008) Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut 57:1561–1565PubMedCrossRef
16.
Zurück zum Zitat Ingkakul T, Sadakari Y, Ienaga J, Satoh N, Takahata S, Tanaka M (2010) Predictors of the presence of concomitant invasive ductal carcinoma in intraductal. Ann Surg 251:70–75PubMedCrossRef Ingkakul T, Sadakari Y, Ienaga J, Satoh N, Takahata S, Tanaka M (2010) Predictors of the presence of concomitant invasive ductal carcinoma in intraductal. Ann Surg 251:70–75PubMedCrossRef
17.
Zurück zum Zitat Sipos B, Frank S, Gress T, Hahn SA, Klöppel G (2009) Pancreatic intraepithelial neoplaia revisited and updated. Pancreatology 9:45–54PubMedCrossRef Sipos B, Frank S, Gress T, Hahn SA, Klöppel G (2009) Pancreatic intraepithelial neoplaia revisited and updated. Pancreatology 9:45–54PubMedCrossRef
18.
Zurück zum Zitat Bartsch DK, Sina-Frey M, Ziegler A, Hahn SA, Przypadlo E, Kress R, Gerdes B, Rieder H (2001) Update of familial pancreatic cancer in Germany. Pancreatology 1:510–516PubMedCrossRef Bartsch DK, Sina-Frey M, Ziegler A, Hahn SA, Przypadlo E, Kress R, Gerdes B, Rieder H (2001) Update of familial pancreatic cancer in Germany. Pancreatology 1:510–516PubMedCrossRef
19.
Zurück zum Zitat Langer P, Gress TM, Bartsch DK (2010) Pancreatic cancer screening in individuals at risk- too early for a general implementation on a health care basis. Gut 59:1006–1007CrossRef Langer P, Gress TM, Bartsch DK (2010) Pancreatic cancer screening in individuals at risk- too early for a general implementation on a health care basis. Gut 59:1006–1007CrossRef
20.
Zurück zum Zitat Fritz S, Klauss M, Bergmann F, Hackert T, Hartwig W, Strobel O, Bundy BD, Büchler MW, Werner J (2012) Small (Sendai negative) branch-duct IPMNs: not harmless. Ann Surg 256:313–320PubMedCrossRef Fritz S, Klauss M, Bergmann F, Hackert T, Hartwig W, Strobel O, Bundy BD, Büchler MW, Werner J (2012) Small (Sendai negative) branch-duct IPMNs: not harmless. Ann Surg 256:313–320PubMedCrossRef
21.
Zurück zum Zitat Aichler M, Seiler C, Tost M, Siveke J, Mazur PK, Da Silva-Buttkus P, Bartsch DK, Langer P, Chiblak S, Dürr A, Höfler H, Klöppel G, Müller-Decker K, Brielmeier M, Esposito I (2012) Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. J Pathol 226:723–734PubMedCrossRef Aichler M, Seiler C, Tost M, Siveke J, Mazur PK, Da Silva-Buttkus P, Bartsch DK, Langer P, Chiblak S, Dürr A, Höfler H, Klöppel G, Müller-Decker K, Brielmeier M, Esposito I (2012) Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. J Pathol 226:723–734PubMedCrossRef
22.
Zurück zum Zitat Schneider R, Slater EP, Sina M, Habbe N, Fendrich V, Matthäi E, Langer P, Bartsch DK (2011) German national case collection for familial pancreatic cancer (FaPaCa) ten years experience. Fam Cancer 10:323–330PubMedCrossRef Schneider R, Slater EP, Sina M, Habbe N, Fendrich V, Matthäi E, Langer P, Bartsch DK (2011) German national case collection for familial pancreatic cancer (FaPaCa) ten years experience. Fam Cancer 10:323–330PubMedCrossRef
23.
Zurück zum Zitat Brune K, Abe T, Canto M, O’Malley L, Klein AP, Maitra A, Volkan Adsay N, Fishman EK, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH (2006) Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Path 30:1067–1076PubMed Brune K, Abe T, Canto M, O’Malley L, Klein AP, Maitra A, Volkan Adsay N, Fishman EK, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH (2006) Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Path 30:1067–1076PubMed
24.
Zurück zum Zitat Nehra D, Ovaride VM, Mino-Kenudson M, Thayer SP, Ferrone CR, Wargo JA, Muzikansky A, Finkelstein D, Warshaw AL, Castillo F (2012) Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter? Pancreatology 12:358–363PubMed Nehra D, Ovaride VM, Mino-Kenudson M, Thayer SP, Ferrone CR, Wargo JA, Muzikansky A, Finkelstein D, Warshaw AL, Castillo F (2012) Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter? Pancreatology 12:358–363PubMed
25.
Zurück zum Zitat Shi C, Goggins M, Maitra A, Canto M, Ali S, Schulick R, Palmisano E, Hruban RH (2009) Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 15(24):7737–7743PubMedCrossRef Shi C, Goggins M, Maitra A, Canto M, Ali S, Schulick R, Palmisano E, Hruban RH (2009) Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 15(24):7737–7743PubMedCrossRef
26.
Zurück zum Zitat Salvia R, Crippa S, Partelli S, Armatura G, Malleo G, Paini M, Pea A, Bassi C (2010) Differences between main-duct and branch-duct intraductal papillary mucinous neoplasms of the pancreas. World J Gastrointest Surg 2:342–346PubMedCrossRef Salvia R, Crippa S, Partelli S, Armatura G, Malleo G, Paini M, Pea A, Bassi C (2010) Differences between main-duct and branch-duct intraductal papillary mucinous neoplasms of the pancreas. World J Gastrointest Surg 2:342–346PubMedCrossRef
27.
Zurück zum Zitat Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C, Fishman EK, Brune K, Axilbund J, Griffin C, Ali S, Richman J, Jagannath S, Kantsevoy SV, Kalloo AN (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4:766–781PubMedCrossRef Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C, Fishman EK, Brune K, Axilbund J, Griffin C, Ali S, Richman J, Jagannath S, Kantsevoy SV, Kalloo AN (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4:766–781PubMedCrossRef
28.
Zurück zum Zitat Poley JW, Kluijt I, Gouma DJ, Harinck F, Wagner A, Aalfs C, van Eijck CH, Cats A, Kuipers EJ, Nio Y, Fockens P, Bruno MJ (2009) The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 104:2175–2181PubMedCrossRef Poley JW, Kluijt I, Gouma DJ, Harinck F, Wagner A, Aalfs C, van Eijck CH, Cats A, Kuipers EJ, Nio Y, Fockens P, Bruno MJ (2009) The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 104:2175–2181PubMedCrossRef
29.
Zurück zum Zitat Verna EC, Hwang C, Stevens PD, Rotterdam H, Stavropoulos SN, Sy CD, Prince MA, Chung WK, Fine RL, Chabot JA, Frucht H (2010) Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 16:5028–5037PubMedCrossRef Verna EC, Hwang C, Stevens PD, Rotterdam H, Stavropoulos SN, Sy CD, Prince MA, Chung WK, Fine RL, Chabot JA, Frucht H (2010) Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 16:5028–5037PubMedCrossRef
30.
Zurück zum Zitat Al-Sukhni W, Borgida A, Rothenmund H, Holter S, Semotiuk K, Grant R, Wilson S, Moore M, Narod S, Jhaveri K, Haider MA, Gallinger S (2011) Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg 30 [Epub ahead of print] Al-Sukhni W, Borgida A, Rothenmund H, Holter S, Semotiuk K, Grant R, Wilson S, Moore M, Narod S, Jhaveri K, Haider MA, Gallinger S (2011) Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg 30 [Epub ahead of print]
31.
Zurück zum Zitat Vasen HF, Wasser M, van Mil A, Tollenaar RA, Konstantinovski M, Gruis NA, Bergman W, Hes FJ, Hommes DW, Offerhaus GJ, Morreau H, Bonsing BA, de Vos tot Nederveen Cappel WH (2011) Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 140:850–856PubMedCrossRef Vasen HF, Wasser M, van Mil A, Tollenaar RA, Konstantinovski M, Gruis NA, Bergman W, Hes FJ, Hommes DW, Offerhaus GJ, Morreau H, Bonsing BA, de Vos tot Nederveen Cappel WH (2011) Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 140:850–856PubMedCrossRef
32.
Zurück zum Zitat Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114–1147PubMedCrossRef Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114–1147PubMedCrossRef
Metadaten
Titel
Multiple small “imaging” branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia?
verfasst von
D. K. Bartsch
K. Dietzel
M. Bargello
E. Matthaei
G. Kloeppel
I. Esposito
J. T. Heverhagen
T. M. Gress
E. P. Slater
P. Langer
Publikationsdatum
01.03.2013
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 1/2013
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-012-9582-y

Weitere Artikel der Ausgabe 1/2013

Familial Cancer 1/2013 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.